Earnings Call Summary | Staar Surgical(STAA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Staar Surgical(STAA.US) Q1 2024 Earnings Conference
The following is a summary of the STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript:
以下是STAAR外科公司（STAA）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
STAAR Surgical posted Q1 2024 net sales of $77.4 million, exceeding estimates due to a 9% increase in ICL sales.
Gross profit for Q1 2024 was $61 million or 78.9% of net sales, a slight increase compared to last year's 78.3%.
The company reported a net loss of $3.3 million or $0.07 loss per share due to a foreign currency exchange loss of $2.3 million.
The forecast for fiscal 2024 annual sales is between $335 million and $340 million.
Q2 2024 is projected to have revenue of about $95 million based on current trends.
由於ICL銷售額增長9％，STAAR Surgical公佈的2024年第一季度淨銷售額爲7,740萬美元，超出預期。
2024年第一季度的毛利爲6,100萬美元，佔淨銷售額的78.9％，與去年的78.3％相比略有增長。
該公司報告稱，由於外幣匯兌虧損230萬美元，淨虧損330萬美元，每股虧損0.07美元。
預計2024財年的年銷售額在3.35億美元至3.4億美元之間。
根據目前的趨勢，預計2024年第二季度的收入約爲9500萬美元。
Business Progress:
業務進展：
EVO ICL lens technology showed strong growth across major regions.
The company launched STAAR University and the Stella ordering system to improve surgeon efficiency.
STAAR's largest ever deal with Dr. Robert Lin and IQ Laser Vision in the U.S. promises substantial growth.
U.S. quarterly sales hit a record high of $5 million, and strategic investments were made in China, the U.S., India, and Brazil.
ICL sales increased across all regions: 9% in Asia-Pacific, 11% in EMEA, and 15% in the U.S., with the aim to make EVO ICL preferred for patients with minus 6 and above diopters.
Plans to increase their team in China to over 100 members by year's end.
They continue to compete effectively by upgrading services and staying technologically ahead.
EVO ICL 鏡頭技術在主要地區表現出強勁的增長。
該公司推出了STAAR大學和Stella訂購系統，以提高外科醫生的效率。
STAAR與羅伯特·林博士和IQ Laser Vision在美國達成的有史以來最大的一筆交易有望實現大幅增長。
美國季度銷售額創歷史新高，達到500萬美元，並在中國、美國、印度和巴西進行了戰略投資。
所有地區的ICL銷售額均有所增長：亞太地區爲9％，歐洲、中東和非洲爲11％，美國爲15％，目的是使EVO ICL成爲屈光度爲負6及以上的患者的首選。
計劃到年底將他們在中國的團隊增加到100多名成員。
他們繼續通過升級服務和保持技術領先地位來進行有效競爭。
More details: Staar Surgical IR
更多詳情： 星光手術紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。